-

Rejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and Launch

BEDFORD, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a privately held clinical-stage company based in Bedford, MA, dedicated to elevating uterine health through innovative biomaterial therapies, today announced the closing of a $25 million financing, with new and existing investors including ClavystBio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital, and Sparta Group.

“Uterine health has been underserved for too long, and this financing puts us in a position to change that."

Share

The proceeds will be used to build the foundation for the Juveena Hydrogel System, Rejoni’s first product. Juveena is designed to support endometrial healing within the uterine cavity following endometrial trauma associated with intrauterine surgery, a leading cause of intrauterine adhesions. Rejoni expects to scale manufacturing and supply operations, invest in market access, physician and patient engagement, and prepare for commercial launch of Juveena when approved by the U.S. FDA.

“Uterine health has been underserved for too long, and this financing puts us in a position to change that. We are building the infrastructure, commercial readiness, market access, and physician engagement to ensure we can move quickly when Juveena is approved,” said John Nealon, Chief Executive Officer of Rejoni, Inc.

“This financing marks an important milestone in Rejoni’s evolution from building the science to preparing for launch. John and the team have the experience and drive to execute on this opportunity, and I remain fully committed to this mission,” said Amar Sawhney, Founder and Chairman of Rejoni, Inc.

About Rejoni, Inc.

Rejoni, Inc. is a privately held company based in Bedford, MA focused on the development and commercialization of gynecological products using its proprietary biomaterials. The company, founded in June 2020, is the latest by serial entrepreneur Amar Sawhney who also founded Confluent Surgical, Ocular Therapeutix, and Augmenix, Inc. More information about Rejoni can be found at www.rejoni.com.

About the Juveena Hydrogel System

The Juveena Hydrogel System is an investigational hydrogel system designed specifically to help reduce the incidence and severity of intrauterine adhesions (IUAs). The system uses a proprietary transcervical catheter to place a soft, temporary hydrogel spacer within the uterine cavity, acting as a spacer during the healing process. Juveena is pending FDA approval and is not available for sale or commercial distribution.

Contacts

Nicole Shugrue
VP Market Access & Development, Rejoni, Inc.
Nicole.Shugrue@Rejoni.com

Rejoni, Inc. LogoRejoni, Inc. Logo

Rejoni, Inc.


Release Versions

Contacts

Nicole Shugrue
VP Market Access & Development, Rejoni, Inc.
Nicole.Shugrue@Rejoni.com

More News From Rejoni, Inc.

Rejoni Announces First Commercial Case Using the Juveena® Hydrogel System at CCRM Fertility of New Jersey

BURLINGTON, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a commercial-stage women's health company focused on uterine health, today announced that the first commercial procedure using the Juveena Hydrogel System has been performed by Serena H. Chen, MD, Founding Partner and Director of Advocacy, at CCRM Fertility of New Jersey in Livingston, N.J. Intrauterine adhesions (IUAs), the hallmark of Asherman's syndrome, form when the uterine lining is injured, most often after hysteroscopic surgery or uterin...

Rejoni Showcases FDA-Approved Juveena® Hydrogel System at AAGL 2026 Global Congress in Boston Alongside Pivotal Trial Results Published in Fertility and Sterility

BURLINGTON, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a commercial-stage women’s health company focused on uterine health, today announced its participation in the AAGL 55th Global Congress on Minimally Invasive Gynecologic Surgery (MIGS), taking place Nov. 13-16, 2026, at the Hynes Convention Center in Boston. At the meeting, results from the Juveena pivotal trial will be featured in an oral presentation during the Scientific Sessions. The trial results are published in Fertility and Sterility, th...

Rejoni Receives FDA Approval of the Juveena® Hydrogel System to Reduce Intrauterine Adhesions Following Hysteroscopic Adhesiolysis

BEDFORD, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a commercial-stage women's health company focused on uterine health, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA P250051) for the Juveena Hydrogel System. The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions. Intraute...
Back to Newsroom